Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-AMI: Dapagliflozin in Acute Myocardial Infarction
NCT04717986Completed
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in acute myocardial infarction (AMI) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 12 months. Started Jan 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT04717986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717986.